Related references
Note: Only part of the references are listed.Recurrent nasopharyngeal carcinoma: hyperfractionation of IMRT improves outcomes
David Killock
NATURE REVIEWS CLINICAL ONCOLOGY (2023)
Envisioning clinical trials as complex interventions
Kristian D. Stensland et al.
CANCER (2022)
Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial
Yuan Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Current status and advances of immunotherapy in nasopharyngeal carcinoma
Jian-Ying Xu et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)
Cross-Sectional Survey of Clinical Trials of Stem Cell Therapy for Heart Disease Registered at ClinicalTrials.gov
Rong Yang et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Comparison of Publication of Pediatric Probiotic vs Antibiotic Trials Registered on ClinicalTrials.gov
Madison Riddell et al.
JAMA NETWORK OPEN (2021)
A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma
Anne W. M. Lee et al.
EUROPEAN JOURNAL OF CANCER (2021)
Nasopharyngeal carcinoma: an evolving paradigm
Kenneth C. W. Wong et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Raju K. Vaddepally et al.
CANCERS (2020)
Characteristics of Clinical Trials relating to COVID-19 registered at ClinicalTrials.gov
Yuhui Wang et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2020)
Trends in FDA drug approvals over last 2 decades: An observational study
Angelika Batta et al.
JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE (2020)
Immunotherapy as sensitizer for local radiotherapy
Ben G. L. Vanneste et al.
ONCOIMMUNOLOGY (2020)
Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy
Quynh Thu Le et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Clinical Trials Focusing on Drug Control and Prevention of Ventilator-Associated Pneumonia: A Comprehensive Analysis of Trials Registered on ClinicalTrials.gov
Lingmin Chen et al.
FRONTIERS IN PHARMACOLOGY (2019)
Management of locally recurrent nasopharyngeal carcinoma
Anne W. M. Leea et al.
CANCER TREATMENT REVIEWS (2019)
The Reciprocity between Radiotherapy and Cancer Immunotherapy
Yifan Wang et al.
CLINICAL CANCER RESEARCH (2019)
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Characterization of PD-L1 and PD-1 Expression and CD8+Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma
Noppadol Larbcharoensub et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2018)
Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians
Sophie Outh-Gauer et al.
CANCER TREATMENT REVIEWS (2018)
Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model
Yingcheng Wu et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Randomization in Clinical Trials Permuted Blocks and Stratification
Kristine Broglio
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)
Brigette B. Y. Ma et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer
Wei You et al.
JOURNAL OF CANCER (2018)
A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics A Review
Julia A. Beaver et al.
JAMA ONCOLOGY (2018)
Changes in Disease Failure Risk of Nasopharyngeal Carcinoma over Time: Analysis of 749 Patients with Long-Term Follow-Up
Xu Liu et al.
JOURNAL OF CANCER (2017)
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
Valsamo Anagnostou et al.
CLINICAL CANCER RESEARCH (2017)
Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?
Robert Kemp et al.
BMC MEDICINE (2017)
Integrated pathway analysis of nasopharyngeal carcinoma implicates the axonemal dynein complex in the Malaysian cohort
Yoon-Ming Chin et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Perceived information gain from randomized trials correlates with publication in high-impact factor journals
Evangelos Evangelou et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Randomisation to protect against selection bias in healthcare trials
R. Kunz et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2007)
A listing of human tumor antigens recognized by T cells
N Renkvist et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2001)